Volume 32, Number 2—February 2026
Emerging Infection Networks Letter
Candida auris Testing by the Antimicrobial Resistance Laboratory Network, United States, 2022–2023
Jessica E. Laury, Kaitlin Forsberg, Elizabeth L. Berkow, Sophie Jones, D. Joseph Sexton, Dawn M. Sievert, Shawn R. Lockhart, Jeremy A.W. Gold1
, and Meghan Lyman1
, and Meghan Lyman1
Table
Clinical isolates of Candida auris, by region and body site, Antimicrobial Resistance Laboratory Network, United States, 2022–2023
| Characteristic |
No. (%) isolates |
||
| All, n = 8,033 |
2022, n = 3,064 |
2023, n = 4,969 |
|
| Region where specimen was collected | |||
| Central | 37 (0) | 2 (0) | 35 (1) |
| Mid-Atlantic | 513 (6) | 156 (5) | 357 (7) |
| Midwest | 904 (11) | 329 (11) | 575 (12) |
| Mountain | 526 (7) | 288 (9) | 238 (5) |
| Northeast | 1,512 (19) | 665 (22) | 847 (17) |
| Southeast | 1,672 (21) | 647 (21) | 1,025 (21) |
| West | 1,967 (24) | 775 (25) | 1,192 (24) |
| Not reported |
902 (11) |
202 (7) |
700 (14) |
| Body site | |||
| Blood | 2,856 (36) | 1,185 (39) | 1,671 (34) |
| Respiratory | 715 (9) | 277 (9) | 438 (9) |
| Urine | 2,598 (32) | 933 (30) | 1,665 (34) |
| Wound | 1,026 (13) | 393 (13) | 633 (13) |
| Other | 838 (10) | 276 (9) | 562 (11) |
1These senior authors contributed equally to this article.
Page created: December 30, 2025
Page updated: February 19, 2026
Page reviewed: February 19, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.